Ito Shoko, Fujiwara Shin-Ichiro, Mashima Kiyomi, Umino Kento, Minakata Daisuke, Nakano Hirofumi, Yamasaki Ryoko, Kawasaki Yasufumi, Sugimoto Miyuki, Ashizawa Masahiro, Yamamoto Chihiro, Hatano Kaoru, Okazuka Kiyoshi, Sato Kazuya, Oh Iekuni, Ohmine Ken, Suzuki Takahiro, Muroi Kazuo, Kanda Yoshinobu
Division of Hematology, Department of Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi, 329-0498, Japan.
Ann Hematol. 2017 May;96(5):719-724. doi: 10.1007/s00277-017-2933-x. Epub 2017 Feb 1.
The development of acute myeloid leukemia (AML) in patients with untreated chronic lymphocytic leukemia (CLL) is rare. We experienced a 65-year-old man who developed AML with aberrant CD7 expression and monoallelic CEBPA mutation during watchful waiting for CLL. He failed to achieve complete response (CR) by standard induction therapy for AML. We retrospectively reviewed 27 patients who developed AML with untreated CLL published between 1973 and 2016. The median age at diagnosis of AML was 68 years, and the median duration between the diagnoses of AML and CLL was 4.2 years. Diagnosis of AML and CLL was made simultaneously in 16 patients. The CR rate of AML was 42.9%, and the median survival was only 1.5 months after the diagnosis of AML. Patients who achieved CR tended to survive longer than those who did not. Our results demonstrated that the development of AML in patients with untreated CLL was associated with a poor response to chemotherapy and an extremely poor prognosis.
未经治疗的慢性淋巴细胞白血病(CLL)患者发生急性髓系白血病(AML)的情况较为罕见。我们诊治了一名65岁男性,其在对CLL进行观察等待期间发生了伴有异常CD7表达和单等位基因CEBPA突变的AML。他接受AML标准诱导治疗后未达到完全缓解(CR)。我们回顾性分析了1973年至2016年间发表的27例未经治疗的CLL患者发生AML的病例。AML诊断时的中位年龄为68岁,AML与CLL诊断之间的中位间隔时间为4.2年。16例患者同时诊断出AML和CLL。AML的CR率为42.9%,AML诊断后的中位生存期仅为1.5个月。达到CR的患者往往比未达到CR的患者存活时间更长。我们的结果表明,未经治疗的CLL患者发生AML与化疗反应不佳及预后极差相关。